Direct Activation of BAX by BTSA1 Overcomes Apoptosis Resistance in Acute Myeloid Leukemia

Area of Science:

• Molecular biology
• Cancer research
• Drug discovery

Background:

• The BCL-2 protein family regulates apoptosis, a crucial process in cell death.
• Overexpression of anti-apoptotic BCL-2 proteins promotes cancer development and therapeutic resistance by inhibiting BAX.
• Targeting BAX, a key mediator of apoptosis, is a potential strategy for cancer treatment.

Purpose of the Study:

• To discover and characterize BTSA1, a novel activator of the pro-apoptotic protein BAX.
• To evaluate the efficacy of BTSA1 in inducing apoptosis in leukemia cells and patient samples.
• To assess the therapeutic potential of BTSA1 in preclinical models of acute myeloid leukemia (AML).

Main Methods:

• High-affinity binding assays to determine BTSA1's interaction with BAX.
• Conformational change analysis of BAX upon BTSA1 treatment.
• Apoptosis assays in leukemia cell lines and primary patient samples.
• In vivo studies using human acute myeloid leukemia (AML) xenografts in mice.

Main Results:

• BTSA1 selectively binds to BAX's N-terminal activation site, inducing conformational changes and BAX-mediated apoptosis.
• BTSA1 effectively triggered apoptosis in leukemia cells and patient samples while sparing normal cells.
• Sensitivity to BTSA1 was correlated with BAX expression levels and cytosolic conformation.
• BTSA1 treatment suppressed AML xenografts and improved host survival without observable toxicity.

Conclusions:

• Direct activation of BAX using BTSA1 is a viable therapeutic strategy for AML.
• BTSA1 demonstrates potent anti-leukemic activity and a favorable safety profile in preclinical models.
• Further development of BTSA1 holds promise for a new class of targeted cancer therapies.